• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Dysregulated Chemokine Signaling in Cystic Fibrosis Lung Disease: A Potential Therapeutic Target.囊性纤维化肺病中趋化因子信号传导失调:一个潜在的治疗靶点。
Curr Drug Targets. 2016;17(13):1535-44. doi: 10.2174/1389450117666151209120516.
2
Harnessing Neutrophil Survival Mechanisms during Chronic Infection by : Novel Therapeutic Targets to Dampen Inflammation in Cystic Fibrosis.利用慢性感染期间中性粒细胞存活机制:抑制囊性纤维化炎症的新型治疗靶点
Front Cell Infect Microbiol. 2017 Jun 30;7:243. doi: 10.3389/fcimb.2017.00243. eCollection 2017.
3
The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease.上皮钠离子通道(ENaC)作为囊性纤维化肺病的治疗靶点。
Expert Opin Ther Targets. 2018 Aug;22(8):687-701. doi: 10.1080/14728222.2018.1501361. Epub 2018 Jul 26.
4
Current Concepts and Controversies in Innate Immunity of Cystic Fibrosis Lung Disease.囊性纤维化肺病固有免疫的当前概念与争议
J Innate Immun. 2016;8(6):531-540. doi: 10.1159/000446840. Epub 2016 Jul 1.
5
Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation.白细胞介素-17在囊性纤维化肺部感染与炎症中的病理生理学及治疗干预
Infect Immun. 2016 Aug 19;84(9):2410-21. doi: 10.1128/IAI.00284-16. Print 2016 Sep.
6
Innate immunity in cystic fibrosis lung disease.囊性纤维化肺病中的固有免疫。
J Cyst Fibros. 2012 Sep;11(5):363-82. doi: 10.1016/j.jcf.2012.07.003. Epub 2012 Aug 20.
7
Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding.地高辛用于囊性纤维化气道炎症:安全性、药代动力学及剂量探索的初步评估
Ann Am Thorac Soc. 2017 Feb;14(2):220-229. doi: 10.1513/AnnalsATS.201608-649OC.
8
Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy.囊性纤维化肺病中的炎症:发病机制与治疗。
J Cyst Fibros. 2015 Jul;14(4):419-30. doi: 10.1016/j.jcf.2015.03.003. Epub 2015 Mar 23.
9
Atypical activation of the unfolded protein response in cystic fibrosis airway cells contributes to p38 MAPK-mediated innate immune responses.囊性纤维化气道细胞中未折叠蛋白反应的非典型激活有助于 p38 MAPK 介导的先天免疫反应。
J Immunol. 2012 Dec 1;189(11):5467-75. doi: 10.4049/jimmunol.1103661. Epub 2012 Oct 26.
10
Hypoxic epithelial necrosis triggers neutrophilic inflammation via IL-1 receptor signaling in cystic fibrosis lung disease.在囊性纤维化肺病中,缺氧性上皮坏死通过白细胞介素-1受体信号传导引发嗜中性粒细胞炎症。
Am J Respir Crit Care Med. 2015 Apr 15;191(8):902-13. doi: 10.1164/rccm.201409-1610OC.

引用本文的文献

1
miRNA-target gene network analysis in siblings with cystic fibrosis and phenotypic variability.囊性纤维化及表型变异性同胞中的微小RNA-靶基因网络分析
Turk J Med Sci. 2025 Apr 28;55(4):1014-1023. doi: 10.55730/1300-0144.6054. eCollection 2025.
2
Elevated Immunoglobulin G as a Predictor of Progression to Severe Lung Disease in Cystic Fibrosis: A Longitudinal Cohort Study.免疫球蛋白G升高作为囊性纤维化进展为严重肺部疾病的预测指标:一项纵向队列研究
J Clin Med. 2025 Jun 18;14(12):4331. doi: 10.3390/jcm14124331.
3
Elexacaftor/tezacaftor/ivacaftor (ETI) therapy modifies the expression of interferon beta and inflammatory genes in the airways of adult patients with cystic fibrosis: a pilot study.依列卡福妥/替扎卡福妥/依伐卡托(ETI)疗法改变成年囊性纤维化患者气道中干扰素β和炎症基因的表达:一项试点研究。
Mol Cell Biochem. 2025 Jun 25. doi: 10.1007/s11010-025-05331-x.
4
Targeting the MEK1/2 pathway to combat infection and inflammation in cystic fibrosis.靶向MEK1/2信号通路以对抗囊性纤维化中的感染和炎症。
mBio. 2025 Jul 9;16(7):e0077525. doi: 10.1128/mbio.00775-25. Epub 2025 May 27.
5
Effects of Oral Amino Acid Supplementation on Physical Activity, Systemic Inflammation, and Quality of Life in Adult Patients with Cystic Fibrosis: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Pilot Study.口服补充氨基酸对成年囊性纤维化患者身体活动、全身炎症及生活质量的影响:一项单中心、随机、双盲、安慰剂对照的试点研究。
Nutrients. 2025 Apr 2;17(7):1239. doi: 10.3390/nu17071239.
6
Neutrophil-Derived Proteases in Lung Inflammation: Old Players and New Prospects.中性粒细胞衍生蛋白酶在肺部炎症中的作用:旧角色与新前景。
Int J Mol Sci. 2024 May 17;25(10):5492. doi: 10.3390/ijms25105492.
7
Impact of 1-Year Supplementation with High-Rich Docosahexaenoic Acid (DHA) on Clinical Variables and Inflammatory Biomarkers in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial.富含二十二碳六烯酸(DHA)的 1 年补充剂对儿科囊性纤维化临床变量和炎症生物标志物的影响:一项随机双盲对照试验。
Nutrients. 2024 Mar 27;16(7):970. doi: 10.3390/nu16070970.
8
Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies.囊性纤维化肺部炎症基因及其与囊性纤维化跨膜电导调节剂治疗的相关性。
Genes (Basel). 2023 Oct 20;14(10):1966. doi: 10.3390/genes14101966.
9
Genome-wide DNA methylation and transcriptome expression profiles of peripheral blood mononuclear cells in patients with systemic sclerosis with interstitial lung disease.系统性硬皮病伴间质性肺病患者外周血单个核细胞全基因组 DNA 甲基化和转录组表达谱。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 Jun 28;48(6):829-836. doi: 10.11817/j.issn.1672-7347.2023.220538.
10
MSCs interaction with the host lung microenvironment: An overlooked aspect?间充质干细胞与宿主肺部微环境的相互作用:被忽视的方面?
Front Immunol. 2022 Nov 15;13:1072257. doi: 10.3389/fimmu.2022.1072257. eCollection 2022.

本文引用的文献

1
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.针对携带Phe508del CFTR纯合突变的囊性纤维化患者使用鲁马卡托-依伐卡托。
N Engl J Med. 2015 Oct 29;373(18):1783-4. doi: 10.1056/NEJMc1510466.
2
Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.鲁马卡托和依伐卡托用于囊性纤维化患者的治疗:当前证据与未来前景
Ther Adv Respir Dis. 2015 Dec;9(6):313-26. doi: 10.1177/1753465815601934. Epub 2015 Sep 28.
3
Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy.囊性纤维化肺病中的炎症:发病机制与治疗。
J Cyst Fibros. 2015 Jul;14(4):419-30. doi: 10.1016/j.jcf.2015.03.003. Epub 2015 Mar 23.
4
Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor.接受依伐卡托治疗的携带G551D突变的囊性纤维化患者血液白细胞的变化。
J Cyst Fibros. 2016 Jan;15(1):67-73. doi: 10.1016/j.jcf.2015.02.010. Epub 2015 Mar 11.
5
The low PLC-δ1 expression in cystic fibrosis bronchial epithelial cells induces upregulation of TRPV6 channel activity.囊性纤维化支气管上皮细胞中PLC-δ1的低表达诱导TRPV6通道活性上调。
Cell Calcium. 2015 Jan;57(1):38-48. doi: 10.1016/j.ceca.2014.11.005. Epub 2014 Nov 18.
6
The protein kinases TPL2 and EGFR contribute to ERK1/ERK2 hyper-activation in CFTRΔF508-expressing airway epithelial cells exposed to Pseudomonas aeruginosa.蛋白激酶TPL2和表皮生长因子受体(EGFR)在暴露于铜绿假单胞菌的表达囊性纤维化跨膜传导调节因子ΔF508(CFTRΔF508)的气道上皮细胞中,促成细胞外信号调节激酶1/2(ERK1/ERK2)的过度激活。
Biochem Biophys Res Commun. 2013 Nov 22;441(3):689-692. doi: 10.1016/j.bbrc.2013.10.030. Epub 2013 Oct 25.
7
A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.一项关于BIIL 284 BS(一种白三烯B4受体拮抗剂)治疗儿童和成人囊性纤维化肺部疾病的随机双盲、安慰剂对照2期试验。
J Cyst Fibros. 2014 Mar;13(2):148-55. doi: 10.1016/j.jcf.2013.12.009. Epub 2014 Jan 17.
8
Expression of microRNA-93 and Interleukin-8 during Pseudomonas aeruginosa-mediated induction of proinflammatory responses.在铜绿假单胞菌介导的促炎反应诱导过程中 microRNA-93 和白细胞介素-8 的表达。
Am J Respir Cell Mol Biol. 2014 Jun;50(6):1144-55. doi: 10.1165/rcmb.2013-0160OC.
9
A novel Pseudomonas aeruginosa-derived effector cooperates with flagella to mediate the upregulation of interleukin 8 in human epithelial cells.一种新型铜绿假单胞菌衍生效应物与鞭毛协同作用,介导人上皮细胞白细胞介素 8 的上调。
Microb Pathog. 2014 Jan;66:24-8. doi: 10.1016/j.micpath.2013.12.001. Epub 2013 Dec 19.
10
The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment.EGF-EGFR 信号通路在肝癌炎症微环境中的作用。
J Cell Mol Med. 2014 Feb;18(2):218-30. doi: 10.1111/jcmm.12153. Epub 2013 Nov 25.

囊性纤维化肺病中趋化因子信号传导失调:一个潜在的治疗靶点。

Dysregulated Chemokine Signaling in Cystic Fibrosis Lung Disease: A Potential Therapeutic Target.

作者信息

Guan Xiaoqing, Hou Yuning, Sun Fei, Yang Zhe, Li Chunying

机构信息

Department of Biochemistry and Molecular Biology, Wayne State University School of Medicine. 540 E. Canfield Avenue, 5312 Scott Hall, Detroit, MI 48201, USA.

出版信息

Curr Drug Targets. 2016;17(13):1535-44. doi: 10.2174/1389450117666151209120516.

DOI:10.2174/1389450117666151209120516
PMID:26648071
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6500735/
Abstract

CF lung disease is characterized by a chronic and non-resolving activation of the innate immune system with excessive release of chemokines/cytokines including IL-8 and persistent infiltration of immune cells, mainly neutrophils, into the airways. Chronic infection and impaired immune response eventually lead to pulmonary damage characterized by bronchiectasis, emphysema, and lung fibrosis. As a complete knowledge of the pathways responsible for the exaggerated inflammatory response in CF lung disease is lacking, understanding these pathways could reveal new therapeutic targets, and lead to novel treatments. Therefore, there is a strong rationale for the identification of mechanisms and pathways underlying the exaggerated inflammatory response in CF lung disease. This article reviews the role of inflammation in the pathogenesis of CF lung disease, with a focus on the dysregulated signaling involved in the overexpression of chemokine IL-8 and excessive recruitment of neutrophils in CF airways. The findings suggest that targeting the exaggerated IL-8/IL-8 receptor (mainly CXCR2) signaling pathway in immune cells (especially neutrophils) may represent a potential therapeutic strategy for CF lung disease.

摘要

囊性纤维化肺部疾病的特征是先天性免疫系统的慢性且无法消退的激活,伴有趋化因子/细胞因子(包括白细胞介素-8)的过度释放,以及免疫细胞(主要是中性粒细胞)持续浸润到气道中。慢性感染和免疫反应受损最终导致以支气管扩张、肺气肿和肺纤维化为特征的肺部损伤。由于缺乏对导致囊性纤维化肺部疾病中过度炎症反应的途径的全面了解,了解这些途径可能会揭示新的治疗靶点,并带来新的治疗方法。因此,有充分的理由去识别囊性纤维化肺部疾病中过度炎症反应背后的机制和途径。本文综述了炎症在囊性纤维化肺部疾病发病机制中的作用,重点关注参与趋化因子白细胞介素-8过表达和囊性纤维化气道中中性粒细胞过度募集的失调信号传导。研究结果表明,针对免疫细胞(尤其是中性粒细胞)中过度的白细胞介素-8/白细胞介素-8受体(主要是CXCR2)信号通路可能是囊性纤维化肺部疾病的一种潜在治疗策略。